Article
Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as…
BioMed Research International · 2014 · Tomasz Gondek, author Mariusz Szajewski, author Jarosław Szefel, author Ewa Aleksandrowicz-Wrona, author Ewa Skrzypczak-Jankun, author Jerzy Jankun, author Wieslawa Lysiak-Szydlowska, author Giovanni Luca Gravina, Academic Editor
Key facts
| Title | Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer |
|---|---|
| First author | Tomasz Gondek, author Mariusz Szajewski, author Jarosław Szefel, author Ewa Aleksandrowicz-Wrona, author Ewa Skrzypczak-Jankun, author Jerzy Jankun, author Wieslawa Lysiak-Szydlowska, author Giovanni Luca Gravina, Academic Editor |
| Journal | BioMed Research International |
| Published | Jan 3, 2014 |
| DOI | 10.1155/2014/102478 |
| Devices mentioned | K013168, K013492, K843077, K843710 |
| Product codes mentioned | DGC, GGP, LGC |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1